Not Signed In - NeoRecormon Gains European Approval For Convenient Once Weekly Treatment Of Anaemia In Patients With Solid Cancers
Mon, 15 Jan 2007 08:00 AM EST
... Roche announced today that it has received European marketing approval for a simple and convenient once weekly subcutaneous injection of NeoRecormon (epoetin beta) 30,000 IU for the treatment of anaemia in patients with solid cancers receiving chemotherapy. [click link for full article] ...
Related Topics
- MMA
- Morbidity & Mortality Weekly Report
- Vaccine Testing & Approval
- Atherosclerosis
- Black Alder
- Seizures (in about half of patients)
- Vaccinations For HIV/AIDs Patients
- What Your Female Patients Want to Know About Bladder Control
- Smoking Cessation and Continued Risk in Cancer Patients
- Other cancers
- Unusual Childhood Cancers
- Unusual Cancers of Childhood
- Treatment
- Approximately one-half of patients with small tumors will get back useful hearing in the affected ear after surgery.
- Cancers of the larynx, esophagus, liver, and colon
- Treatments
- X-linked sideroblastic anemia
- Skin damage due to skin cancers
- European Goldenrod
- Cancers
email this page
print this page
bookmark this page
feedback on this page
